|
gptkbp:instanceOf
|
gptkb:drug
gptkb:PARP_inhibitor
|
|
gptkbp:approvalYear
|
2014
December 2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XX46
|
|
gptkbp:brand
|
gptkb:Lynparza
|
|
gptkbp:CASNumber
|
763113-22-0
|
|
gptkbp:chemicalFormula
|
C24H23FN4O3
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:combinationTherapy
|
gptkb:bevacizumab
gptkb:abiraterone
|
|
gptkbp:contraindication
|
hypersensitivity to olaparib
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
gptkb:Merck_&_Co.
|
|
gptkbp:drugClass
|
gptkb:antineoplastic_agent
|
|
gptkbp:EMAApprovalDate
|
December 2014
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
gptkbp:genericName
|
gptkb:olaparib
|
|
gptkbp:halfLife
|
11.9 hours
|
|
gptkbp:indication
|
gptkb:cancer
pancreatic cancer
prostate cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
PARP enzyme inhibition
|
|
gptkbp:metabolism
|
hepatic (CYP3A4/5)
|
|
gptkbp:patent
|
gptkb:AstraZeneca
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prescriptionRequired
|
https://www.lynparza.com/
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
diarrhea
fatigue
cough
dyspnea
decreased appetite
dysgeusia
|
|
gptkbp:usedFor
|
BRCA-mutated cancers
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca
gptkb:Merck_&_Co.
gptkb:AstraZeneca_US
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lynparza
|